Combination therapy for advanced liver cancer
Part of Cancer clinical trials.
This trial tests a combination of treatments for liver cancer that cannot be removed by surgery. It uses a special radiation therapy called Y90 along with other drugs to see if they work better together.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer that cannot be surgically removed and it hasn't spread outside the liver.
- You are between 18 and 80 years old.
- Your liver function is good (Child-Pugh class A) and you are in generally good health (ECOG 0 or 1).
- You have not had prior systemic therapy or Y90 treatment for your cancer.
- You do not have active autoimmune disease or a history of chronic autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines three treatments: Y-90 radioembolization (targeted radiation to liver tumors), two immunotherapy drugs (durvalumab and tremelimumab), and a targeted oral drug (zanzalintinib) to see if this combination can shrink or control liver cancer that cannot be removed by surgery or transplant. It may be an option for people whose cancer has not spread beyond the liver and who have not had prior systemic treatment.
This trial tests a combination of two immunotherapy drugs, nivolumab and ipilimumab, as a first treatment for liver cancer that cannot be removed by surgery or has come back after local treatments.
This trial is testing a new combination therapy for liver cancer that cannot be surgically removed. It uses an immune-boosting drug (atezolizumab), a drug that blocks blood flow to tumors (bevacizumab), and a type of chemotherapy that is delivered directly into the liver artery (HAIC). This combination may help shrink liver tumors and improve outcomes.
This trial tests a new combination for liver cancer that cannot be surgically removed yet. It uses tiny radioactive beads (yttrium-90) to deliver radiation directly to the tumor, along with immunotherapy drugs and a targeted therapy to shrink the tumor, with the hope that it can later be surgically removed.
This trial tests a combination of radioactive microspheres (Yttrium-90) with targeted immunotherapy drugs (camrelizumab and apatinib) for people with liver cancer (HCC) that cannot be surgically removed. It may be an option for those with intermediate-stage disease who haven't had prior systemic therapy.
This trial studies whether combining three treatments—an immunotherapy drug (Atezo), a blood-vessel-blocking drug (Bev), and a radioactive bead treatment (SIRT-Y90)—can help patients with advanced liver cancer that cannot be surgically removed. The goal is to see if using all three together works better than using fewer treatments.
Hear when a new Unresectable Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.